









Markets
/
Stocks
/
nasdaq-snti
/

Senti Biosciences Inc

SNTI

0.930USD

+0.108+13.15%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

24.46MMarket Cap

LossP/E TTM



Senti Biosciences Inc

0.930

+0.108+13.15%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Senti Biosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Senti Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 164 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Senti Biosciences Inc's Score

Industry at a Glance

Industry Ranking

164 / 392

Overall Ranking

315 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Senti Biosciences Inc Highlights

StrengthsRisks

Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Undervalued

The company’s latest PE is -0.40, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.88M shares, decreasing 17.31% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 628.70K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

11.500

Target Price

+1298.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Senti Biosciences Inc is 6.81, ranking 208 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.81

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Senti Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Senti Biosciences Inc is 6.41, ranking 286 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.40, which is -115.53% below the recent high of 0.06 and -290.70% above the recent low of -1.56.

Score

Industry at a Glance

Previous score

6.41

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 164/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Senti Biosciences Inc is 8.50, ranking 105 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 15.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

11.500

Target Price

+1298.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Senti Biosciences Inc

SNTI

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Senti Biosciences Inc is 4.77, ranking 341 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.15 and the support level at 0.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.47

Change

0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Sell

RSI(14)

38.688

Neutral

STOCH(KDJ)(9,3,3)

28.724

Buy

ATR(14)

0.079

Low Volatility

CCI(14)

-129.026

Sell

Williams %R

66.081

Sell

TRIX(12,20)

-0.981

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.929

Buy

MA10

0.980

Sell

MA20

1.034

Sell

MA50

1.306

Sell

MA100

1.547

Sell

MA200

1.961

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Senti Biosciences Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 22.37%, representing a quarter-over-quarter decrease of 16.40%. The largest institutional shareholder is The Vanguard, holding a total of 628.70K shares, representing 2.39% of shares outstanding, with 303.46% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Celadon Partners SPV 24

9.78M

New Enterprise Associates (NEA)

3.78M

Bayer HealthCare LLC

2.81M

+377.99%

PharmaEssentia Corp.

2.11M

Nantahala Capital Management, LLC

888.00K

The Vanguard Group, Inc.

Star Investors

616.07K

+70.70%

8VC GP I, LLC

253.75K

Lu (Timothy K M.D., Ph.D.)

161.63K

Geode Capital Management, L.L.C.

152.84K

+3.75%

Citadel Advisors LLC

82.75K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Senti Biosciences Inc is 1.49, ranking 310 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.